Heslinga Sjoerd C, Peters Mike J, Ter Wee Marieke M, van der Horst-Bruinsma Irene E, van Sijl Alper M, Smulders Yvo M, Nurmohamed Michael T
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, location Reade and VU University Medical Center; and Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands.S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, location Reade, and VU University Medical Center; M.J. Peters, MD, PhD, Department of Internal Medicine, VU University Medical Center; M.M. ter Wee, MSc, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, location VU University Medical Center; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, location Reade, and VU University Medical Center; A.M. van Sijl, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, location Reade, and VU University Medical Center; Y.M. Smulders, Professor, Doctor, Department of Internal Medicine, VU University Medical Center; M.T. Nurmohamed, Professor, Doctor, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, location Reade, and VU University Medical Center.
J Rheumatol. 2015 Oct;42(10):1842-5. doi: 10.3899/jrheum.150193. Epub 2015 Sep 1.
To investigate the effects of changing inflammation on lipid levels in ankylosing spondylitis.
In a cohort of 230 patients, lipid levels were measured at baseline and after 52 weeks of treatment with tumor necrosis factor-α-blocking agents (anti-TNF).
Total cholesterol (TC; +4.6%), low-density lipoprotein cholesterol (+4.3%), and high-density lipoprotein cholesterol (HDL-C; +3.7%) increased upon treatment. Changes were most evident in patients with substantial reduction in inflammatory levels (TC +8.2% vs +1.6% and HDL-C +8.3% vs +2.2% in patients with C-reactive protein ≥ 10 mg/l normalizing upon treatment vs CRP < 10 mg/l throughout treatment period).
Anti-TNF therapy results in lipid changes mostly when inflammation is appreciably modified.
研究强直性脊柱炎炎症变化对血脂水平的影响。
在一组230例患者中，于基线期及使用肿瘤坏死因子-α阻滞剂（抗TNF）治疗52周后测量血脂水平。
治疗后总胆固醇（TC；升高4.6%）、低密度脂蛋白胆固醇（升高4.3%）和高密度脂蛋白胆固醇（HDL-C；升高3.7%）升高。炎症水平大幅降低的患者变化最为明显（治疗后C反应蛋白≥10mg/l恢复正常的患者中TC升高8.2%，而整个治疗期间CRP<10mg/l的患者中TC升高1.6%；HDL-C分别为升高8.3%和升高2.2%）。
抗TNF治疗主要在炎症明显改善时导致血脂变化。
